Interim Report January – March 2022
· Net sales totaled SEK 32,574 (15,723) thousand, with a growth rate of 107%. About SEK 10 million relates to the license agreement in 2021 with Selecta Biosciences. Growth is 91%, adjusted for currency effects. · Gross profit rose by 96% to SEK 29,419 (15,017) thousand. · Operating profit before depreciation and amortization (EBITDA) totaled SEK 11,717 (1,958) thousand. · Operating profit jumped SEK 9,554 thousand and totaled SEK 10,105 (551) thousand. · Comprehensive income for the period improved by SEK 11,476 thousand and totaled SEK 13,083 (1,607) thousand. · Comprehensive